Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients.

Tugce Senturk Kirmizitas Caroline van den Berg Ruben G Boers Jean Helmijr Stavros MakrodimitrisHamit Harun DagMarijn KerkhofsCorine BeaufortJaco Kraan Wilfred F J Van IJckenJoost GribnauPakriti GarkhailGatske Nieuwenhuyzen-de BoerEva-Maria RoesHeleen van BeekhuizenTuba GunelSaskia M Wilting John W M MartensMaurice JansenIngrid A Boere

Published in: Genes (2024)

Our genome-wide Next-Generation Sequencing (NGS) analyses in PARPi-resistant patients identified epigenetic differences in blood before treatment, whereas genomic alterations were more frequently observed after progression. The epigenetic differences at baseline are especially interesting for further exploration as putative predictive biomarkers for PARPi resistance.

Keyphrases

dna methylation
genome wide
copy number
gene expression
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
dna damage
combination therapy